A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
Public ClinicalTrials.gov record NCT03086369. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
Study identification
- NCT ID
- NCT03086369
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Eli Lilly and Company
- Industry
- Enrollment
- 184 participants
Conditions and interventions
Conditions
Interventions
- Gemcitabine Drug
- Nab-paclitaxel Drug
- Olaratumab Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 21, 2017
- Primary completion
- Jan 4, 2021
- Completion
- Jun 16, 2021
- Last update posted
- Jun 27, 2022
2017 – 2021
United States locations
- U.S. sites
- 32
- U.S. states
- 19
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| TGen Clinical Research Services at Scottsdale Healthcare | Scottsdale | Arizona | 85258 | — |
| University of Arizona Cancer Center | Tucson | Arizona | 85724 | — |
| Highlands Oncology Group | Fayetteville | Arkansas | 72703 | — |
| Comprehensive Blood and Cancer Center | Bakersfield | California | 93309 | — |
| St Jude Medical Center | Fullerton | California | 92835 | — |
| TRIO - Translational Research in Oncology-US, Inc. | Los Angeles | California | 90024 | — |
| UCLA Medical Center | Los Angeles | California | 90095 | — |
| Cancer Center of Santa Barbara with Sansum Clinic | Santa Barbara | California | 93105 | — |
| Central Coast Medical Oncology Corporation | Santa Maria | California | 93454 | — |
| Smilow Cancer Hospital at Yale-New Haven | New Haven | Connecticut | 06510 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33901 | — |
| Florida Cancer Specialists and Research Institute | St. Petersburg | Florida | 33705 | — |
| H Lee Moffitt Cancer Center | Tampa | Florida | 33612-9497 | — |
| Fort Wayne Oncology & Hematology | Fort Wayne | Indiana | 46845 | — |
| Cancer Center of Kansas | Wichita | Kansas | 67214 | — |
| Nebraska Methodist Hospital | Omaha | Nebraska | 68114 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89169 | — |
| Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | 03756-0001 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263-0002 | — |
| Monter Cancer Center | Lake Success | New York | 11042 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232-1305 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| Sanford Research/USD | Sioux Falls | South Dakota | 57104 | — |
| Chattanooga Oncology Hematology Associates | Chattanooga | Tennessee | 37404 | — |
| Sarah Cannon Research Institute SCRI | Nashville | Tennessee | 37203 | — |
| Tennessee Oncology PLLC | Nashville | Tennessee | 37203 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232-6307 | — |
| Univ of Texas Health Science Center at San Antonio | San Antonio | Texas | 78229 | — |
| University of Utah School of Medicine | Salt Lake City | Utah | 84112 | — |
| University of Wisconsin-Madison Hospital and Health Clinic | Madison | Wisconsin | 53792-4108 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03086369, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 27, 2022 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03086369 live on ClinicalTrials.gov.